| Name | Title | Contact Details |
|---|
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA? (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.
NavigatorMD, Inc. was founded in 2005 to address the rising demand for an integrated data analysis and health plan management solution. As an insurance broker, Ernest Youngblood, founder of NavigatorMD, watched the progressive increase in health care costs and identified the opportunity for organizations to save money while improving the overall wellness of a plan population. Youngblood led the organization of a multi-disciplinary team of healthcare professionals, ranging from physicians and pharmacologists to benefit consultants and C-Suite executives to develop its first product, Design180®. The intended purpose of this advisory team was to establish an understanding of the problems and hurdles that faced the business community in managing and understanding their health claims spend. This unique insight and knowledge was the basis of its technically sound, business-oriented approach to claims analysis and comprehensive health plan management. NavigatorMD launched its first product in 2008 with the mission of lowering health care costs and adding value to health plans by focusing on manageable costs and utilizing the power of data. Influenced by the concept of value-based insurance design, our health claims data analytics software was created under the advisory of various professionals, including former VP of Strategic H.R. Initiatives at Pitney Bowes, David Hom, who served as an early member of the NavigatorMD's Board of Directors. Early success and escalating interest in the product resulted in the formation of an advisory board comprising several influential experts in the field of Value-Based Insurance Design (VBID). In addition, NavigatorMD received support and referrals from two of the largest pharmaceutical companies in the U.S. that were responsible for funding the development of the Center for Value Based Health Management, among other value-based health care initiatives. NavigatorMD, the first step toward proactive health plan management.
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
The Myers Group is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Mauna Kea Technologies is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.